Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 29 tags : Treatment save search
Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Published: 2021-06-29 (Crawled : 21:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 9.68%
H: 1.96%
C: -6.74%
treatment biotech phase 3 iot enroll
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer Company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers
Published: 2021-06-29 (Crawled : 17:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: 0.31%
H: 3.04%
C: -2.82%
treatment fda potential test therapy cancer gastrointestinal drug cpi-613 milestone designation
Global Graft Versus Host Disease (GVHD): Market Size from 2018 to 2030 and Overview of Treatment Practices and Emerging Drugs
Published: 2021-06-29 (Crawled : 16:00) - prnewswire.com
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.47%
H: 0.89%
C: -0.6%
disease treatment drug
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer
Published: 2021-06-29 (Crawled : 16:00) - globenewswire.com
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: 0.31%
H: 3.04%
C: -2.82%
treatment fda cancer drug cpi-613 granted grant designation
Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
Published: 2021-06-29 (Crawled : 14:15) - biospace.com/
CGEM | $18.9 13.38% 11.8% 1.2M
|
|
| O: -0.42%
H: 4.09%
C: -0.15%
new drug fda clearance treatment fda solid tumors antibody drug clearance
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.08%
H: 0.66%
C: -0.95%
treatment phase 2 trial lupus enroll
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Published: 2021-06-29 (Crawled : 13:00) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.0%
H: 0.32%
C: -0.2%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.08%
H: 1.06%
C: 0.68%
NTLA | $21.16 -1.72% -1.75% 860K
|
Health Technology
|
| O: -2.19%
H: 17.95%
C: 16.17%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 33.33%
H: 0.0%
C: -20.52%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.81%
H: 0.0%
C: -5.95%
AVXL | $3.4 -7.61% -8.24% 2M
|
Health Technology
|
| O: -0.59%
H: 0.17%
C: -17.64%
treatment glioblastoma
Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027
Published: 2021-06-29 (Crawled : 13:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.03%
H: 0.4%
C: -0.08%
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -0.81%
H: 0.82%
C: -4.62%
MNKD | $4.19 0.72% 0.72% 1.8M
|
Health Technology
|
| O: -1.13%
H: 2.1%
C: 0.0%
ITRM | $1.52 -3.8% -3.95% 36K
|
Health Technology
|
| O: 2.95%
H: 1.43%
C: -2.05%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 33.33%
H: 0.0%
C: -20.52%
treatment diagnostic train
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration
Published: 2021-06-29 (Crawled : 13:00) - biospace.com/
OCUL | News | $4.645 -7.1% -7.64% 3.9M
|
Health Technology
|
| O: 1.07%
H: 0.99%
C: -3.1%
treatment ocular collaboration macular
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Published: 2021-06-29 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.5%
H: 0.89%
C: -3.47%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 33.33%
H: 0.0%
C: -20.52%
berubicin treatment fda fast track fast track designation granted grant designation glioblastoma
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
Published: 2021-06-29 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.0%
H: 0.32%
C: -0.2%
satellite treatment rosa europe therapy cancer colorectal cancer approval nivolumab
Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease
Published: 2021-06-29 (Crawled : 12:00) - prnewswire.com
PTN | $1.73 -1.14% 0.0% 59K
|
Health Technology
|
| O: 7.22%
H: 15.17%
C: 15.17%
dry eye disease treatment fda phase 2 eye positive eye disease
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.